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ProfileAlan Trounson Takes the Reins of the CIRMBy the end of 2007, the California Insti-
tute for Regenerative Medicine (CIRM)
will have a new president. Alan Troun-
son, a founding father of stem cell re-
search and professor at Australia’s
Monash University, was recently ap-
pointed to head the world’s richest
funding source for stem cell science.
The event is much anticipated, as pre-
vious president Zach Hall announced
his intent to step down last December
in a dispute over ‘‘facility needs.’’
Trounson is a giant in embryonic and
regenerative medicine. He pioneered
techniques that led to the birth of the
first Australian baby conceived by in vi-
tro fertilization, and he went on to found
eight companies providing infertility
treatments and conducting biotech-
nology research and stem cell studies,
among them Singapore-based Embry-
onic Stem Cell International. By deriv-
ing nerve stem cells from embryonic
stem cells, Trounson illustrated the po-
tential of stem cells to treat neurologi-
cal and other incurable diseases.
Trounson also founded the Australian
Stem Cell Centre (ASCC) at Monash
in 2003 and served as its first director
and CEO.
Trounson spoke by phone from
Australia just days after the bonds
supporting the CIRM’s $3
billion research budget first
went on sale. The con-
clusion of 3 years of legal
wrangling over the insti-
tute’s management seemed
an auspicious time for
Trounson to take the reins.
Given the organization’s
stormy beginnings, it’s per-
haps no surprise that Troun-
son views his role as Virgil to
the institute’s Dante: an es-
cort through the minefields
of clinical trials, regulatory
expectations, a public di-
vided over the field’s ethi-
cality, and provincialism.
‘‘I see myself as being
able to navigate through
the bigger picture,’’ Troun-
son says. He anticipates
being able to see potential hazards
such as science deficiencies or
scale-up problems from far enough
off to evade the rough spots. ‘‘I’ve
been through this with IVF. I see myself
as guiding the discoveries into the
clinic in the most efficient and effective
way.’’
At the press conference announcing
his selection, Trounson had mentioned
a desire to coordinate stem cell re-
search in California with efforts at other
research centers. ‘‘I’d like to avoid du-
plication in the discovery and transla-
tion process and try to enhance our
ability to get the treatments to the
clinic by helping one another. That
will take a collaborative approach,’’
Trounson says. Depending on how
state law and CIRM funding parame-
ters impact the disbursement of insti-
tute grants, he would consider provid-
ing funds to promote joint projects
with industry or even other states and
countries. His goal is to avoid the
pitfalls that he witnessed in Australia,
where scientific infrastructure is
strong but continental isolation can
prevent researchers from working
closely with their natural colleagues.
Here, Trounson’s strong connections
and high regard among stem cell re-
searchers internationally will be a major
asset.
Trounson views the commercial
use of intellectual property rights as
another potential trouble spot. He
describes the situation as a double-
edged sword. On the one hand, Troun-
son says, intellectual property rights to
basic stem cell science can block the
road from discovery to patient treat-
ments. ‘‘If you’ve always got to go to
that company to get the rights to do re-
search or make initial clinical studies, it
can be a terrible handicap to the field,’’
Trounson says. ‘‘Our best interest and
theirs is to make sure that the pipeline
is open.’’ And because the path to the
approval can be long and very expen-
sive, private companies can run out of
funds before the idea is put to use. In-
stead of feeding new areas of re-
search, it runs the risk of growing stag-
nant and dying.
On the other hand, while committed
to the entire portfolio of CIRM science,
which ranges from basic to applied
science, Trounson believes industry
is the best place to pioneer and deliver
supporting technologies, such as re-
agents. Putting the problem in terms
of economics, Trounson says, should
help overcome this obstacle. Supplies
don’t require nearly as much
investment to produce as
therapies, provide a rela-
tively rapid return to share-
holders, and relieve scien-
tists of the burden of
concocting all supplies
from scratch. ‘‘Intellectual
property that relates to
a specific product needs to
be utilized by a company if
it’s going to remain compet-
itive. If there’s any way we
can work these kinds of
things out in discussion
and convince people that
hanging on to the other
type isn’t in their interest, it
would be much better.’’
Similarly, while the Insti-
tute’s current science pro-
gram is very solid, a fewAlan TrounsonCell Stem Cell 1, November 2007 ª2007 Elsevier Inc. 495
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vent them from causing problems in
the future. He points out that any ther-
apy based on embryonic or other plu-
ripotential stem cells would constitute
the use of foreign tissue in a host. En-
listing immunologists to characterize
immune system-stem cell interactions
more fully could only save sleep in
the long run. Along these same lines,
Trounson says, scientists need to ver-
ify the parameters of stem cell perfor-
mance in more animal models before
considering clinical trials with humans.
And if other cells kept in culture are any
guide, cultured stem cells also ex-
perience changes in genetics and
function. One trait that tends to be fa-
vored is rapid division—a feature of
cancer cells—not totipotency. The
need to characterize these alterations
in culture, Trounson says, could be
an opportunity to link stem cell re-
searchers with their counterparts in
oncology.
Back in the days of IVF, Trounson
worked to reassure a skittish public
that the technique conformed to norms
of ethical thought. He did so by educat-
ing Australians about the science and
issues at hand. This experience has
made him a big supporter of CIRM’s
public outreach programs. ‘‘Education496 Cell Stem Cell 1, November 2007 ªneeds to be done at all levels of the
community,’’ he says, ‘‘so that all peo-
ple, not just those who work in this
field, can see a benefit coming from
this investment.’’
At present, Trounson sees a rela-
tively smooth journey ahead at the in-
stitute.Hedoesnot anticipate aconflict
of direction such as the one that devel-
oped while he was leading the ASCC.
While Trounson was still at its helm,
the center drastically narrowed its re-
search priorities from general stem
cell science to focus on developing
therapeutics for blood diseases. At
the same time, the center concen-
trated on treatments that could be
brought to market sooner. ‘‘It wasn’t
the vision I set out for them originally.
Their vision wasn’t the same as mine,’’
Trounson says.
Trounson doesn’t expect such a shift
in focus to crop up at the CIRM. ‘‘I was
much more aligned with the kinds of
things Bob Klein and the CIRM were
talking about: having a much wider
portfolio with basic research but also
assisting and getting those discover-
ies into the clinic.’’
Trounson sees research appli-
cations to the CIRM as being relatively
insulated from economic consider-
ations. By law, an independent2007 Elsevier Inc.committee for peer review evaluates
proposals based on scientific merit.
As president, Trounson won’t sit on
these committees. His influence on
future research will be limited to con-
centrating the requests for proposals
in certain areas where need becomes
critical.
That said, the institute is under the
gun to tap into a strong revenue
stream. It must start repaying the
bonds supporting all its programs 5
years from this fall. That’s a relatively
short time frame to bring any medical
treatment to the clinic, much less any-
thing as controversial as stem cells.
Even major drug companies, which
have the staff and machinery in place
to put therapies through the clinical
testing and commercial pipeline,
would be hard pressed to meet such
a deadline.
Ultimately, Trounson says, he is hon-
ored and excited to have this role to
advance stem cell research. ‘‘I’m com-
ing to a time in my life that I’m satisfied
with what I’ve done in the research
arena. I can make a contribution in a
different way, which accumulates all
those experiences I’ve had in research
and translation, clinical work, and
commercialization. It fits rather nicely
in capping off a career.’’
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